Aminotriazole derivatives as alx agonists

IPC classes for russian patent Aminotriazole derivatives as alx agonists (RU 2492167):

C07D417/14 - containing three or more hetero rings

C07D417/06 - linked by a carbon chain containing only aliphatic carbon atoms

C07D413/14 - containing three or more hetero rings

C07D413/12 - linked by a chain containing hetero atoms as chain links

C07D405/06 - linked by a carbon chain containing only aliphatic carbon atoms

C07D401/14 - containing three or more hetero rings

C07D401/12 - linked by a chain containing hetero atoms as chain links

C07D249/04 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

A61P29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)

A61K31/4192 -

Another patents in same IPC classes:

Compounds suitable for use as raf kinase inhibitors / 2492166

Invention relates to a compound of formula 1:

Polymorphous form of 2-aminothiazole compounds as kinase inhibitor and method of its obtaining / 2491286

Invention relates to polymorphous form of compound

Organic compounds / 2491285

Invention refers to compounds of formula (I), wherein V is specified in -O- or a single bond; W is specified in -N(R⁵)C(O)-, -S(O)_t- and -C(O)O-; X is specified in C(H) or N; Y is specified in S, N(H) or N(CH₃); p means 0 or 2; t means 1 or 2; R¹ is specified in a group consisting of hydrogen, C_1-6alkyl optionally substituted by 1 or 2 halogroups, C_3-7cycloalkylC_1-6alkyl, 2,3-dihydro-1H-indenyl, C₆arC_1-6alkyl optionally substituted by one or two halogroups and heteroarylC_1-6alkyl, wherein a heteroaryl fragment of the heteroarylalkyl group means 5-6-member monocyclic heteroaryl containing 1 or 2 heteroatoms independently specified in a group consisting of nitrogen optionally oxidated, oxygen and sulphur, or a heteroaryl fragment of the heteroarylalkyl group means 9-member bicyclic heteroaryl containing 1 or 2 heteroatoms independently specified in a group consisting of nitrogen, oxygen and sulphur, wherein monocyclic heteroaryl of the heteroarylalkyl group may be optionally substituted by one or two substitutes independently specified in a group consisting a halogroup, a cyanogroup, C_1-6alkyl, haloC_1-6alkyl and C_1-6alkyl-O-C(O)-; R² is specified in a group consisting of hydrogen, C_1-6alkyl optionally substituted by phenoxy, hydroxy C_1-6alkyl, C_3-7cycloalkyl, C_3-7cycloalkylC_1-6alkyl, phenyl optionally substituted by a halogroup, haloC_1-6alkyl, C₆arC_1-6alkyl (optionally substituted by a halogroup, haloC_1-6alkyl or haloC_1-6alkoxygroup), 2-oxo-imidazolidinyl, heterocyclylC_1-6alkyl and heteroarylC_1-6alkyl, wherein heterocyclyl of heterocyclylalkyl means 5- or 6-member monocycle containing oxygen, and wherein a heteroaryl fragment of the heteroarylalkyl group means 5-6-member monocycle containing 1-3 heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, or a heteroaryl fragment of the heteroarylalkyl group means 9- or 10-member bicycle containing 1 to 2 heteroatoms specified in a group consisting of nitrogen and sulphur, wherein monocyclic heteroaryl of the heteroaryl alkyl group may be optionally substituted by 1 or 2 substitutes independently specified in a group consisting of a halogroup, C_1-6alkyl, haloC_1-6alkyl and phenyl optionally substituted by a halogroup; R³ is specified in a group consisting of hydrogen and alkyl; two adjacent R⁴ groups together with carbon atoms whereto attached can form phenyl; R⁵ means hydrogen; or a pharmaceutically acceptable salt thereof.

2h-chromen compound and derivative thereof / 2490266

Invention refers to a 2H-chromen compound or a derivative thereof having action of a S1P₁ agonist. The above may be used for preventing and/or treating a disease caused by undesired lymphocyte filtration, or a disease caused by abnormal cell proliferation or accumulation.

Derivatives of aminopyrazol / 2489426

Invention relates to derivatives of aminopyrazol with the formula of , where A, E, R¹ and R² have values specified in the invention claims, and to their pharmaceutically acceptable salts. Compounds of the formula (I) are agonists of the ALX receptor. Besides, the invention relates to a pharmaceutical composition on the basis of the compound of the formula (I) or its pharmaceutically acceptable salt and to application of these compounds for production of a medicinal agent for prevention or treatment of a disease selected from inflammatory diseases, wheezing diseases, allergic states, HIV-mediated retrovirus infections, cardiovascular diseases, neuroinflammations, neurological disorders, pain, prion-mediated diseases and amiloid-mediated diseases; and for modulation of immune responses.

Mmp-2 and/or mmp-9 inhibitor / 2487131

Invention provides to a high degree a safe pharmaceutical drug which is effective for diseases caused by MMP-2 and/or MMP-9. The pharmaceutical drug contains, as an active ingredient, at least one member selected from a group which consists of thiazole derivatives of formula (1): where R¹ is a phenyl group which can have 1-3 lower alkoxy groups as substitutes in the phenyl ring, and R² is a pyridyl group which can have 1-3 carboxyl groups as substitutes in the pyridine ring, or salts thereof.

Benzothiazole cyclobutyl amine derivatives as ligands of histamine h<sub>3</sub>-receptors, pharmaceutical composition based thereon, method for selective modulation of effects of histamine h<sub>3</sub>-receptors and method of treating condition or disorder modulated by histamine h<sub>3</sub>-receptors

Benzothiazole cyclobutyl amine derivatives as ligands of histamine h₃-receptors, pharmaceutical composition based thereon, method for selective modulation of effects of histamine h₃-receptors and method of treating condition or disorder modulated by histamine h₃-receptors / 2487130

Invention relates to compounds of formula (I), stereoisomers, trans- and cis-isomers, racemates or pharmaceutically acceptable salts thereof, having modulating activity on histamine H₃-receptors. In formula (I) m equals 0; one of R₁ and R₂ is selected from a group which includes hydrogen, C_1-10alkoxycarbonyl, amido-, carboxy-, C_3-8cycloalkyl, halogen, -NR_AR_B, (NR_AR_B)carbonyl, or a group of formula -L₂-R₆; the other of R₁ and R₂ is selected from a group which includes hydrogen, halogen; each of R_3a and R_3b is independently selected from a group which includes hydrogen; each of R₄ and R₅ is independently selected from a group which includes C_1-10alkyl and C_1-10hydroxyalkyl; or R₄ and R₅, taken together with a nitrogen atom to which each is bonded, form a heteroaromatic ring of the type (a) or (b), where Q₁ is O or C; Q₂ is -N(R₂₀)-; R₂₀ is selected from a group which includes hydrogen and C_1-10alkoxycarbonyl; each of p1 and p2 is independently equal to 1, 2 or 3; each of q1, q2, q3, q4 and q5 are independently equal to 0, 1 or 2; and wherein each carbon atom in the ring is substituted with hydrogen or 0, 1 or 2 substitutes, independently selected from a group which includes hydrogen, hydroxy group, fluorine, C_1-10alkyl, C_1-10hydroxyalkyl and C_1-10fluoroalkyl; R₆ is a phenyl, heterocycle or heterocycloC_1-4alkyl, wherein the heterocycle is a 4-6-member aromatic or non-aromatic ring which contains 1 or 2 heteroatoms independently selected from N, O and S, optionally condensed with a benzene ring, wherein the phenyl or heterocycle can be unsubstituted or optionally substituted with one or more substitutes independently selected from a group which includes C_1-4alkoxy, C_1-4alkyl, cyano, halogen and oxo-; L is a bond or C_1-4alkylene; L₂ is a bond, C_1-4alkylene, -C(=O)-, -SO₂N(R_14a)-, -N(R_14a)SO₂-, -C(O)N(R_14a)-, -N(R_l4a)C(O)- or -N(R₁₅)-; R₁₀ is selected from a group which includes hydrogen; R_14a is selected from a group which includes hydrogen; R₁₅ is selected from a group which includes hydrogen; and R_A and R_B are independently selected from a group which includes hydrogen, C_1-10alkyl, C_1-10acyl, C_1-4halogenalkyl, C_1-10alkoxycarbonyl, C_3-8cycloalkyl and C_3-8cycloalkylcarbonyl. The invention also relates to a pharmaceutical composition which contains compounds of formula (I), a method for selective modulation of effects of histamine H₃-receptors, use of said compounds in producing a medicament for treating a condition or disorder modulated by histamine H₃-receptors, as well as specific compounds of formula (I).

Chiral cis-imidazolines / 2487127

Described are novel chiral cis-imidazolines selected from a group which includes 2-{4-[(4S,5R)-2-(2-tert-butyl-4-ethoxypyrimidin-5-yl)-4,5-bis-(4-chlorophenyl)-4,5-dimethyl-4,5-dihydroimidazole-1-carbonyl]-piperazin-1-yl}-acetamide, [(4S,5R)-2-(2-tert-butyl-4-ethoxypyrimidin-5-yl)-4,5-bis-(4-chlorophenyl)-4,5-dimethyl-4,5-dihydroimidazol-1-yl]-[4-(1,1-dioxohexahydrothiopyran-4-yl)-piperazin-1-yl]-methanone, [(4S,5R)-2-(2-tert-butyl-4-ethoxypyrimidin-5-yl)-4,5-bis-(4-chlorophenyl)-4,5-dimethyl-4,5-dihydroimidazol-1-yl]-[4-(3-methanesulphonylpropyl)-piperazin-1-yl]-methanone, 2-{4-[(4S,5R)-2-(6-tert-butyl-4-ethoxypyridin-3-yl)-4,5-bis-(4-chlorophenyl)-4,5-dimethyl-4,5-dihydroimidazole-1-carbonyl]-piperazin-1-yl}-N,N-bis-(2-methoxyethyl)-acetamide. 2-{1-[(48;5K)-2-(6-tert-butyl-4-ethoxypyridin-3-yl)-4,5-bis-(4-chlorophenyl)-4,5-dimethyl-4,5-dihydroimidazole-1-carbonyl]-piperidin-4-yl}-acetamide and others described by the general structural formula (I), and pharmaceutical composition containing said compounds.

Novel amide derivative and use thereof as medicinal agent / 2487124

Invention relates to an amide derivative of formula (I), where A is benzene or pyridine, where the benzene or pyridine optionally contain 1 or 2 or 3 identical or different substitutes selected from an alkyl containing 1-6 carbon atoms, a cycloalkyl containing 3-6 carbon atoms, an alkoxy containing 1-6 carbon atoms, a halogen atom, nitro, cyano, alkylsulphonyl containing1-6 carbon atoms, amino, cyclic amine selected from 1,1-di-oxoisothiazolidinyl, 2-oxooxazolidinyl, oxopyrrolidinyl, 1,1-dioxothiazinyl and 2-oxoimidazolidinyl optionally having a substitute selected from an alkyl containing 1-6 carbon atoms and an alkylcarbonyl containing a total of 2-7 carbon atoms, acylamino containing a total of 2-7 carbon atoms, and an alkylsulphonyl amino containing 1-6 carbon atoms, wherein the right-side bond is linked to the carbonyl and the left-side bond is linked to the nitrogen atom, R¹ and R² are identical or different and each is a hydrogen, an alkyl containing 1-6 carbon atoms and optionally containing 3 halogen atoms as substitutes, a cycloalkyl containing 3-6 carbon atoms, a phenyl, a halogen atom or a cyano group and R¹ and R² are not a hydrogen atom at the same time, R³ is a hydrogen atom, an alkyl containing 1-6 carbon atoms, an alkenyl containing 2-6 carbon atoms, a cycloalkyl containing 3-6 carbon atoms, or a halogen, R^4a, R^4b and R^4c are each independently a hydrogen atom, an alkyl containing 1-6 carbon atoms, or an oxo, R^5a, R^5b and R^5c are identical or different and each is a hydrogen atom, an alkyl containing 1-6 carbon atoms and optionally containing substitute(s) selected from phenyl, an alkoxy group containing 1-6 carbon atoms, optionally substituted with an alkoxy group containing 1-6 carbon atoms, a phyenylcarbonyloxy group and a hydroxy group, or a phenyl, X is a carbon atom (any of R^4a, R^4b and R^4c can be bonded to a carbon atom, but the carbon atom is not substituted with oxo) or a nitrogen atom (if Y is a single bond, the nitrogen atom can be oxidised to form an N oxide), Y is a single bond, a carbonyl or an oxygen atom, Z¹ and Z² are each independently a carbon atom (substitute R³ is optionally bonded to a carbon atom) or a nitrogen atom, and m equals 1 or 2, a pharmacologically acceptable salt thereof. The amide derivative is used as a preventive/therapeutic drug for treating autoimmune diseases, inflammatory bowel diseases or osteoarthritis.

Dipeptide prodrugs and use thereof / 2486183

Application describes prodrugs being 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)-phenyl]pyridine-3,5-dicarbonitryl derivatives, and a method for preparing them.

Derivatives of aminopyrazol / 2489426

Amide compound / 2479576

Compounds exhibit antagonistic activity towards the EP4 receptor, which enables use thereof as an active ingredient in a pharmaceutical composition for treating chronic kidney disease or diabetic nephropathy.

Method of producing α,ω -bis-(1,5,3-dithiazepinan-3-yl)alkanes / 2478634

Invention relates to organic chemistry and specifically to a method of producing α,ω-bis-(1,5,3-dithiazepinan-3-yl)-alkanes of general formula (1):

3-aza-bicyclo[3,3,0]octane compounds / 2471796

Invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of formula , where R¹ and R² are hydrogen, C_1-4alkyl or fluorine; R³ is a phenyl which is unsubstituted, mono- or disubstituted, where the substitutes are independently selected from a group comprising C_1-4alkyl, C_1-4alkoxy group, trifluoromethyl, trifluoromethoxy group and halogen; 2,3-dihydrobenzofuranyl; 2,3-dihydrobenzo[1,4]dioxynyl; or isoxazolyl, pyridyl, indazolyl, benzofuranyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, pyrrolo[2,1b]thiazolyl, imidazo[ 1,2-a]pyridinyl or imidazo[2,1-b]thiazolyl, where said groups are unsubstituted, mono- or disubstituted, where the substitutes are independently selected from a group comprising C₁-₄alkyl, C_1-4alkoxy group, halogen and trifluoromethyl; A is or ; R⁴ is C_1-4alkyl or -NR⁶R⁷; R⁶ is hydrogen or C_1-4alkyl; R⁷ is hydrogen or C_1-4alkyl; and D is a phenyl which is unsubstituted, mono- or disubstituted, where the substitutes are independently selected from a group comprising C_1-4alkyl, C_1-4alkoxy group, trifluoromethyl and halogen; or a pharmaceutically acceptable salt of such a compound. 3-aza-bicyclo[3.3.0]octane derivatives or a pharmaceutically acceptable salt thereof are used as a medicinal agent having the activity of orexin receptor antagonists.

Novel phenyl pyrrole derivative / 2470917

Invention relates phenyl pyrrole derivatives formula (I) where: A denotes =NOR⁴, O; R⁴ denotes, C₁-C₆ alkyl; R¹ denotes C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen-C₁-C₆ alkyl, halogen-C₁-C₆ alkoxy, NH₂, mono- C₁-C₆ alkylamino, halogen-mono-C₁-C₆ alkylamino, di(C₁-C₆ alkyl)amino, halogen-di-(C₁-C₆ alkyl)amino; or A and R¹ together with the carbon atom with which they are bonded form a 5- or 6-member heterocyclic aromatic group or a heterocyclic group with partially or completely reduced saturation, which can be benzo-condensed, can contain 1-3 heteroatoms selected from N, O and S, which can be substituted and contain 1 or 2 α substitutes; R² denotes phenyl which can be substituted with 1 or 2 α substitutes, or a 6-member heteroaryl group containing 1 or 2 N atoms, which can be substituted with 1 or 2 α substitutes; R³ denotes OH, C₁-C₆ alkoxy, values of α are given in claim 1, or a pharmaceutically acceptable salt thereof.

Method of obtaining a, α,ω-bis-(1, 5, 3-dithiazepinan-3-yl)alkanes / 2466999

Invention relates to method of obtaining α,ω-bis-(1,5,3-dithiazepinan-3-yl)-alkanes, which can be applied as antibacterial, antifungal and antiviral agents, as biologically active complexing agents, selective sorbents and extractants of precious metals, special reagents for suppression of vital activity of bacteria in various technical media (from light industry to oil). Essence of method lies in interaction of α,ω-alkanediamine with 1,3,6-oxadithiapinane in presence of catalyst SmCl₃·6H₂O with mole ratio α,ω-alkanediamine : 1,3,6-oxadithiapinane : SmCl₃·6H₂O=10:20:(0.3-0.7) at temperature ~20°C and atmospheric pressure for 2.5-3.5 h. Output of α,ω-bis-(1,5,3-dithiazepinan-3-yl)-alkanes (1) constitutes 72-85%.

Synthesis of epothiliones, intermediate products thereof, analogues and use thereof / 2462463

Invention relates to a compound of formula or a pharmaceutically acceptable salt thereof, in which R₁ denotes hydrogen or C_1-6alkyl; R₂ denotes isooxazolyl group, substituted with C_1-6alkyl; R_B denotes -CF₃, -CHF₂, -CH₂F, or C_1-6alkyl. The invention also relates to pharmaceutical compositions for treating cancer which contain the disclosed compounds.

Substituted heteroaryl derivatives / 2459806

Invention refers to new substituted heteroaryl derivatives of general formula I: , wherein: A means N, CR^7-10, with A at the most twice meaning N; W means O, S or NR⁴, the values B, C, R^7-10 are presented in clause 1 of the patent claim. The method for preparing the compound I is described.

Novel pyridone derivatives, having mch antagonist activity, and medicinal agent containing said compounds / 2453543

Invention relates to compounds of general formula (I),

Hiv-inhibiting 5-(hydroxymethylene- and aminomethylene)substituted pyrimidines / 2452737

Invention relates to novel substituted pyrimidine derivatives, having HIV replication inhibiting properties, or pharmaceutically acceptable salts thereof. In formula (1): R¹ denotes hydrogen; R² and R³ independently denote hydrogen; R⁷ and R⁸ denote C_1-6alkyl; R⁴ denotes cyano; R⁹ denotes C_1-6alkyl optionally substituted with cyano, C_2-6alkenyl substituted with cyano, C_2-6alkynyl optionally substituted with cyano; R⁵ denotes C_1-6alkyl optionally substituted with Ar or Het; C_2-6alkenyl optionally substituted with Ar or Het; C_2-6alkynyl optionally substituted with Ar or Het; C_3-7cycloalkyl; Ar; Het; R⁶ denotes H, Het; Y denotes -OR¹¹, -NR¹²R¹³; R¹¹ denotes hydrogen or C_1-6alkyl optionally substituted with hydroxy, C_1-6alkoxy or pyridyl; R¹² denotes hydrogen or C_1-6alkyl; R¹³ denotes hydrogen or C_1-6alkyl; or R¹² and R¹³ together with a nitrogen atom, which is substituted by said two substitutes, form a morpholinyl; imidazolyl; X denotes -NR¹-; Het denotes 5- or 6-member completely saturated ring, where one or two ring members are heteroatoms, each independently selected from nitrogen and sulphur, and where the rest of the ring members are carbon atoms; and where any member of the heterocycle with a nitrogen heteroatom can optionally be substituted with C_1-6alkyl; where the 5- or 6-member ring can optionally be annelated with a benzene or thiophene ring; each aryl independently denotes phenyl or phenyl substituted with one substitute selected from C_1-6alkoxy.

Compounds suitable for use as raf kinase inhibitors / 2492166

Invention relates to a compound of formula 1:

FIELD: medicine, pharmaceutics.

SUBSTANCE: described are novel aminitriazole derivatives of formula (I), where A is phenyl, heterocyclyl or propan-1,3-diyl; E is *-C_1-4alkyl-O-, -CH=CH- or , where asterisks stand for bond, through which binding with R¹; Q- O or S occurs; R³ is hydrogen, C_1-4alkyl, cyclopropyl, C_1-4alkoxy-C_1-4alkyl, benzyl or -CH₂CH₂C(O)O-tert-Bu; R¹ is pyridyl or phenyl, possibly substituted with halogen, C_1-4alkyl, C_1-4alkoxy, C_1-4fluoroalkyl, C_1-4fluoroalkoxy, di-( C_1-3alkyl)amino or C_1-4alkoxy-C_1-2alkyl; and R² is -CO-C_1-3alkyl,-CF₂-C_1-3alkyl or -SO₂-C_1-3alkyl; or their pharmaceutically acceptable salts, pharmaceutical composition, which contains them.

EFFECT: obtaining novel compounds for treatment of inflammatory disease or Alzheimer's disease.

20 cl, 105 ex, 1 tbl

The text descriptions are given in facsimile form.

1. The compound of formula (I)

where a represents a phenyl or heterocyclyl group, where two deputies are in the 1,3-position; or a represents propan-1,3-diyl;
E is the battle *-C _1-4alkyl-O-, -CH=CH - or

where the asterisks indicate the bond through which the connection occurs with R¹;
Q represents O or S;
R³represents hydrogen, C_1-4alkyl, cyclopropyl,_1-4alkoxy-C_1-4alkyl, benzyl or-CH₂CH₂C(O)O-tert-Bu;
R¹represents pyridyloxy or phenyl group that is unsubstituted, mono-, di - or tizamidine, where the substituents independently selected from the group comprising halogen, C_1-4alkyl, C_1-4alkoxygroup,_1-4foralkyl,_1-4forelcosure, di-(C_1-3alkyl)amino group and C_1-4alkoxy-C_1-2alkyl; and
R²represents a-CO-C_1-3alkyl, -CF₂-C_1-3alkyl or-SO₂-C_1-3alkyl; where the term heterocyclyl means 5 - or 6-membered monocyclic aromatic ring containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur;
where the term "1,3-position" means that two atoms of the phenyl or heterocyclyl group that is attached to triazoltiolom fragment and to the residue R²accordingly, isolated from each other by one atom;
or pharmaceutically acceptable salt of such compounds.

2. The compound of formula (I) according to claim 1, where
A represents a phenyl-1,3-diyl, furan-2,5-diyl, xazal-2,4-diyl, oxazol-2,5-diyl, thiophene-2,4-diyl, thiophene-2,5-diyl, thiazol-2,4-diyl, thiazole-2,5-diyl, pyridine-2,4-diyl, pyridine-2,6-diyl or propane-1,3-diyl; or a pharmaceutically acceptable salt of such compounds.

3. The compound of formula (I) according to claim 1, where
And represents furan-2,5-diyl, oxazol-2,4-diyl with R²attached in 2-position, oxazol-2,4-diyl with R²attached in 4-position, oxazol-2,5-diyl with R²attached in the 2-position of the thiophene-2,5-diyl or thiazole-2,4-diyl with R²attached at the 4-position; or a pharmaceutically acceptable salt of such compounds.

4. The compound of formula (I) according to claim 1, where a represents furan-2,5-diyl or thiophene-2,5-diyl; or a pharmaceutically acceptable salt of such compounds.

5. The compound of formula (I) according to claim 1, where a represents propan-1,3-diyl; or a pharmaceutically acceptable salt of such compounds.

6. The compound of formula (I) according to one of claims 1 to 5, where
E represents *-(C₁-C₄)alkyl-O - or-CH=CH-,
where the asterisk indicates the bond through which the connection occurs with R¹;
or pharmaceutically acceptable salt of such compounds.

7. The compound of formula (I) according to one of claims 1 to 5, where E is a

where the asterisk indicates the bond through which the connection occurs with R¹;
or pharmaceutically acceptable with the ü of such compounds.

8. The compound of formula (I) according to claim 7, where R³represents hydrogen or methyl; or a pharmaceutically acceptable salt of such compounds.

9. The compound of formula (I) according to one of claims 1 to 5, where
R¹represents phenyl, which is unsubstituted, mono - or disubstituted where the substituents are independently selected from the group comprising halogen, C_1-4alkyl, C_1-4alkoxygroup, trifluoromethyl, cryptometer and dimethylaminopropyl;
or pharmaceutically acceptable salt of such compounds.

10. The compound of formula (I) of claim 8, where
R¹represents phenyl, which is unsubstituted, mono - or disubstituted where the substituents are independently selected from the group comprising halogen, C_1-4alkyl, C_1-4alkoxygroup, trifluoromethyl, cryptometer and dimethylaminopropyl;
or pharmaceutically acceptable salt of such compounds.

11. The compound of formula (I) according to one of claims 1 to 5, where R²represents a-CO-C_1-3alkyl; or a pharmaceutically acceptable salt of such compounds.

12. The compound of formula (I) according to claim 1, selected from the group including:
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(4-triptoreline)acrylamide;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-what ethoxyphenyl)-2-methoxazole-4-carboxylic acid; and
2-chlorbenzoyl ether [2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
or pharmaceutically acceptable salt of such compounds.

13. The compound of formula (I) according to claim 1, selected from the group including:
[2-(5-oxohexyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(4-chlorophenyl)acrylamide;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(2-triptoreline)acrylamide;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(3-trifloromethyl)acrylamide;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-o-tolylacetate;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(2-chloro-4-forfinal)acrylamide;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-m-tolylacetic;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-p-tolylacetate;
(E)-N-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(4-methoxyphenyl)acrylamide;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3, 5dimethylphenyl)-2-methoxazole-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-triptoreline)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfinal)-2-methoxazole-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(4-chlorophenyl)oxazol-4-carboxylic acid
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-m-tolyloxy-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-trifloromethyl)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)-2-methoxazole-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-methoxy-4-were)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(4-forfinal)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-m-tolyloxy-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-methoxyphenyl)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-triptoreline)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-trifloromethyl)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-o-tolyloxy-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-ethyl-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-cyclopropyl-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-metil)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfinal)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(3-acetylphenyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
2-chlorbenzoyl ether [2-(3-acetylphenyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
[2-(5,5-divergences)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(5-methansulfonate-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-dimethylaminophenyl)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
2-chlorbenzoyl ether [2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
2-chlorbenzoyl ether [2-(4-acetylpyridine-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-[3-(2-methoxyethyl)phenyl]oxazol-4-carboxylic acid;
[2-(6-acetylpyridine-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-methoxymethyl)oxazol-4-carboxylic acid;
[2-(2-acetylthiazole-4-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(4-acetylpyridine-2-ylmethyl-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(2-acetylpyridine-4-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
2-chlorbenzoyl ether [2-(2-acetylpyridine-4-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
[2-(5-acetylthiophene-3-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid; and
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-m-tolyltriazole-4-carboxylic acid;
or pharmaceutically acceptable salt of such compounds.

14. The compound of formula (I) according to claim 1, selected from the group including:
[2-(3-acetylisoniazid-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-isopropoxyphenyl)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-[3-(2-isopropoxyphenyl)phenyl]oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-m-tolyloxy-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)-2-methoxazole-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-m-tolyloxy-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-triptoreline)oxazol-4-carboxylic acid;
[2-(5-acetyl is open-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfinal)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-dimethylaminophenyl)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-trifloromethyl)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(4-forfinal)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-trifloromethyl)oxazol-4-carboxylic acid;
[2-(5-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-methoxyphenyl)oxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfinal)thiazole-4-carboxylic acid;
[2-(2-acetylthiazole-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
2-chlorbenzoyl ether [2-(2-acetylthiazole-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
(E)-N-[2-(2-acetylthiazole-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(4-triptoreline)acrylamide;
[2-(2-acetyloxy-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
2-chlorbenzoyl ether [2-(5-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid;
[2-(4-acetylthiophene-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-CT is about acid;
(E)-N-[2-(5-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(4-triptoreline)acrylamide;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-m-tolyloxy-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)-2-methoxazole-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-phenyloxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-triptoreline)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfinal)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-dimethylaminophenyl)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-trifloromethyl)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(4-forfinal)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-trifloromethyl)oxazol-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-methoxyphenyl)oxazol-4-carboxylic acid;
(E)-N-[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(4-triptoreline)acrylamide;
(E)-N-[2-(4-acetylthiazole-2-ilma who yl)-2H-[1,2,3]triazole-4-yl]-3-(3-trifloromethyl)acrylamide;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-methoxyphenyl)-2-methoxazole-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfinal)-2-methoxazole-4-carboxylic acid;
[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-m-tolyltriazole-4-carboxylic acid;
[2-(4-acetyloxy-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methoxymethyl-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-(2-methoxyethyl)-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-butyl-5-phenyloxazol-4-carboxylic acid;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-isopropyl-5-phenyloxazol-4-carboxylic acid;
(E)-N-[2-(4-acetylthiazole-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]-3-(2-triptoreline)acrylamide;
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-benzyl-5-phenyloxazol-4-carboxylic acid;
tert-butyl ether 3-{4-[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-ylcarbonyl]-5-phenyloxazol-2-yl}propionic acid;
[2-(2-acetyloxy-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-forfair)-2-methoxazole-4-carboxylic acid;
[2-(2-acetyloxy-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-m-tolyloxy-4-carboxylic acid;
[2-(2-acetyloxy the ol-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(3-chlorophenyl)-2-methoxazole-4-carboxylic acid;
[2-(2-acetyloxy-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-m-tolyloxy-4-carboxylic acid;
[2-(2-acetyloxy-5-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide of 2-methyl-5-(3-trifloromethyl)oxazol-4-carboxylic acid;
2-chlorbenzoyl ether [2-(2-acetyloxy-4-ylmethyl)-2H-[1,2,3]triazole-4-yl]carbamino acid; and
[2-(5-acetylfuran-2-ylmethyl)-2H-[1,2,3]triazole-4-yl]amide 5-(6-triptorelin-2-yl)oxazol-4-carboxylic acid;
or pharmaceutically acceptable salt of such compounds.

15. The compound of formula (I) according to claim 1 or its pharmaceutically acceptable salt as a medicine.

16. Pharmaceutical composition having agonistic activity against ALX receptor containing as an active ingredient a compound of the formula (I) according to claim 1 or its pharmaceutically acceptable salt and at least one therapeutically inert excipient.

17. The use of the compounds of formula (I) according to claim 1 or its pharmaceutically acceptable salts for preparing a medicinal product intended for the prevention or treatment of inflammatory diseases.

18. The compound of formula (I) according to claim 1 or its pharmaceutically acceptable salt for the prevention or treatment of inflammatory diseases.

19. The use of the compounds of formula (I) according to claim 1 or its pharmaceutically acceptable salts for the preparation, the drug money, intended for the prevention or treatment of Alzheimer's disease.

20. The compound of formula (I) according to claim 1 or its pharmaceutically acceptable salt for the prevention or treatment of Alzheimer's disease.